BRCA1 cross-talk with hormone receptors

Cancer Treatment and Research

Volumn 147, Issue , 2009, Pages 53-72

  Rosen, Eliot M ^a   Ma, Yongxian ^b   Fan, Saijun ^b  

^a GEORGETOWN UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; AROMATASE; BRCA1 PROTEIN; CYCLIN D1; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; HORMONE RECEPTOR; MIFEPRISTONE; PROGESTERONE RECEPTOR;

ANDROGEN RELEASE; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER INHIBITION; CANCER MODEL; CANCER PREVENTION; CANCER RISK; DIETARY INTAKE; ENVIRONMENTAL EXPOSURE; ESTROGEN ACTIVITY; EXPERIMENTAL MOUSE; FUNCTIONAL GENOMICS; GENE EXPRESSION REGULATION; GENE INACTIVATION; GENE LOSS; HORMONAL REGULATION; HORMONE INHIBITION; HORMONE RECEPTOR INTERACTION; HUMAN; LIGAND BINDING; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN FUNCTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; BREAST TUMOR;

BREAST NEOPLASMS; HUMANS;

EID: 79953767629     PISSN: 09273042     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-09463-2_5     Document Type: Article

References (110)

1. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66-71. (Pubitemid 24345325)
2. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995;378:789-792. (Pubitemid 26004412)
3. Tavtigian SV, Simard J, Rommens J, Couch F, Shattuck-Eidens D, Neuhausen S, Merajver S, Thorlacius S, Offit K, Stoppa-Lyonnet D, Belanger C, Bell R, Berry S, Bogden R, Chen Q, Davis T, Dumont M, Frye C, Hattier T, Jammulapati S, Janecki T, Jiang P, Kehrer R, Leblanc JF, Goldgar DE, et al. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet 1996;12:333-337. (Pubitemid 26080098)
4. Merajver SD, Frank TS, Xu J, Pham TM, Calzone KA, Bennett-Baker P, Chamberlain J, Boyd J, Garber JE, Collins FS et al. Germline BRCA1 mutations and loss of the wild-type allele in tumors from families with early onset breast and ovarian cancer. Clin Cancer Res. 1995;1:539-544.
5. Rosen EM, Fan S, Pestell RG, Goldberg ID. BRCA1 gene in breast cancer. J Cell Physiol. 2003;196:19-41. (Pubitemid 36676440)
6. Gudmundsdottir K, Ashworth A. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance ofgenomic stability. Oncogene 2006;25:5864-5874 Review. (Pubitemid 44453442)
7. Tirkkonen M, Johannsson O, Agnarsson BA, Olsson H, Ingvarsson S, Karhu R, Tanner M, Isola J, Barkardottir RB, Borg A, Kallioniemi OP. Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line muta-tions. Cancer Res. 1997;57:1222-1227. (Pubitemid 27152540)
8. Xu X, Weaver Z, Linke SP, Li C, Gotay J, Wang XW, Harris CC, Ried T, Deng CX. Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Mol Cell. 1999;3:389-395. (Pubitemid 29290679)
9. Weaver Z, Montagna C, Xu X, Howard T, Gadina M, Brodie SG, Deng CX, Ried T. Mammary tumors in mice conditionally mutant for Brca1 exhibit gross genomic instability and centrosome amplification yet display a recurring distribution of geno-mic imbalances that is similar to human breast cancer. Oncogene 2002;21:5097-5107.
10. Thompson D, Easton DF Breast Cancer Linkage Consortium. Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst. 2002;94:1358-1365. (Pubitemid 35154140)
11. Elson DA, Riley RR, Lacey A, Thordarson G, Talamantes FJ, Arbeit JM. Sensitivity of the cervical transformation zone to estrogen-induced squamous carcinogenesis. Cancer Res. 2000;60:1267-1275. (Pubitemid 30151994)
12. Arbeit JM, Howley PM, Hanahan D. Chronic estrogen-induced cervical and vaginal squamous carcinogenesis in human papillomavirus type 16 transgenic mice. Proc Nat Acad Sci USA. 2003;93:2930-2935.
13. de Villiers EM. Relationship between steroid hormone contraceptives and HPV, cervical intraepithelial neoplasia and cervical carcinoma. Int J Cancer. 2003;103:705-758.
14. Liede A, Karlan BY, Narod SA. Cancer risks for male carriers of germline muta-tions in BRCA1 or BRCA2: a review of the literature. J Clin Oncol. 2004;22: 735-742. (Pubitemid 41095079)
15. Lubinski J, Phelan CM, Ghadirian P, Lynch HT, Garber J, Weber B, Tung N, Horsman D, Isaacs C, Monteiro AN, Sun P, Narod SA. Cancer variation associated with the position of the mutation in the BRCA2 gene. Familial Cancer. 2004;3:1-10. (Pubitemid 40655347)
16. Narod SA. Modifiers ofrisk ofhereditary breast cancer. Oncogene 2006;25:5832-5836 Review.
17. Rosen EM, Fan S, Isaacs C. BRCA1 in hormonal carcinogenesis: basic and clinical research. Endocr Relat Cancer. 2005;12:533-548 Review.
18. Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van't Veer L, Garber JE, Evans G, Isaacs C, Daly MB, Matloff E, Olopade OI, Weber BL; Prevention and Observation of Surgical End Points Study Group. Prophylactic oophorectomy in carriers ofBRCA1 or BRCA2 mutations. New Engl J Med 2002;346:1616-1622.
19. Kauff ND, Domchek SM, Friebel TM, Robson ME, Lee J, Garber JE, Isaacs C, Evans DG, Lynch H, Eeles RA, Neuhausen SL, Daly MB, Matloff E, Blum JL, Sabbatini P, Barakat RR, Hudis C, Norton L, Offit K, Rebbeck TR. Risk-reducing salpingo-oophor-ectomy for the prevention of BRCA1-and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol 2008;26:1331-1337.
20. Monteiro AN, August A, Hanafusa H. Evidence for a transcription activation function of BRCA1 C-terminal region. Proc Nat Acad Sci USA 1996;93:13595-13599. (Pubitemid 26424164)
21. Hashizume R, Fukuda M, Maeda I, Nishikawa H, Oyake D, Yabuki Y, Ogata H, Ohta T. The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation. J Biol Chem. 2001;276:14537-14540.
22. Boulton SJ. BRCA1-mediated ubiquitylation. Cell Cycle. 2006;5:1481-1486. (Pubitemid 44091964)
23. Shakya R, Szabolcs M, McCarthy E, Ospina E, Basso K, Nandula S, Murty V, Baer R, Ludwig T. The basal-like mammary carcinomas induced by Brca1 or Bard1 inactivation implicate the BRCA1/BARD1 heterodimer in tumor suppression. Proc Nat Acad Sci USA 2008; Apr 28. [Epublished ahead ofprint].
24. Bork P, Hofmann K, Bucher P, Neuwald AF, Altschul SF, Koonin EV. A superfamily of conserved domains in DNA damage-responsive cell cycle checkpoint proteins. FASEB J. 1997;11:68-76.
25. Thakur S, Zhang HB, Peng Y, Le H, Carroll B, Ward T, Yao J, Farid LM, Couch FJ, Wilson RB, Weber BL. Localization of BRCA1 and a splice variant identifies the nuclear localization signal. Mol Cell Biol. 1997;17:444-452. (Pubitemid 26425634)
26. Rodriguez JA, Henderson BR. Identification of a functional nuclear export sequence in BRCA1. J Biol Chem. 2000;275: 38589-38596. (Pubitemid 32009187)
27. Rajan JV, Wang M, Marquis ST, Chodosh LA. Brca2 is coordinately regulated with Brca1 during proliferation and differentiation in mammalian epithelial cells. Proc Nat Acad Sci USA 1996;93:3078-3083.
28. Thomas JE, Smith M, Tonkinson JL, Rubinfeld B, Polakis P Induction ofphosphoryla-tion of BRCA1 during the cell cycle and after DNA damage. Cell Growth Differen. 1997;8:801-809. (Pubitemid 27287811)
29. Rosen EM, Fan S, Ma Y. BRCA1 regulation of transcription. Cancer Lett. 2006;236:175-185 Review.
30. Hu YF, Li R. Jun Bpotentiates function ofBRCA1 activationdomain 1 (AD1) througha coiled-coil-mediatedinteraction. Genes Dev. 2002;16:1509-1517.
31. Fan S, Wang J, Yuan R, Ma Y, Meng Q, Erdos MR, Pestell RG, Yuan F, Auborn KJ, Goldberg ID, Rosen EM. BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science 1999;284:1354-1356. (Pubitemid 29289660)
32. Zhang Y, Fan S, Meng Q, Ma Y, Katiyar P, Schlegel R, Rosen EM. BRCA1 interaction with human papillomavirus oncoproteins. J Biol Chem. 2005;280:33165-33177. (Pubitemid 41397112)
33. Fan S, Ma YX, Wang C, Yuan RQ, Meng Q, Wang JA, Erdos M, Goldberg ID, Webb P, Kushner PJ, Pestell RG, Rosen EM p300 Modulates the BRCA1 inhibition of estrogen receptor activity. Cancer Res. 2002;62:141-151. (Pubitemid 34073998)
34. Fan S, Ma YX, Wang C, Yuan RQ, Meng Q, Wang JA, Erdos M, Goldberg ID, Webb P, Kushner PJ, Pestell RG, Rosen EM. Role ofdirect interaction in BRCA1 inhibition of estrogen receptor activity. Oncogene 2001;20:77-87. (Pubitemid 32142340)
35. Fan S, Wang JA, Yuan RQ, Ma YX, Meng Q, Erdos MR, Brody LC, Goldberg ID, Rosen EM. BRCA1 as a potential human prostate tumor suppressor: modulation ofproliferation, damageresponsesandexpressionofcellregulatoryproteins. Oncogene 1998;16:3069-3082. (Pubitemid 28297729)
36. Fan S, Yuan R, Ma YX, Meng Q, Goldberg ID, Rosen EM Mutant BRCA1 genes antagonize phenotype of wild type BRCA1. Oncogene 2001;20:8215-8235. (Pubitemid 34038210)
37. Kawai H, Li H, Chun P, Avraham S, Avraham HK Direct interaction between BRCA1 and the estrogen receptor regulates vascular endothelial growth factor (VEGF) transcrip-tion and secretion in breast cancer cells. Oncogene 2002;21:7730-7739. (Pubitemid 35398818)
38. Ma YX, Tomita Y, Fan S, Wu K, Tong Y, Zhao Z, Song LN, Goldberg ID, Rosen EM. Structural determinants of the BRCA1: estrogen receptor interaction. Oncogene 2005;24:1831-1846. (Pubitemid 40462786)
39. Wu LC, Wang ZW, Tsan JT, Spillman MA, Phung A, Xu XL, Yang MC, Hwang LY, Bowcock AM, Baer R. Identification of a RING protein that can interact in vivo with the BRCA1 geneproduct. Nat Genet. 1996;14:430-440. (Pubitemid 26414587)
40. Ruffner H, Joazeiro CA, Hemmati D, Hunter T, Verma IM. Cancer-predisposing muta-tions within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity. Proc Nat Acad Sci USA. 2001;98:5134-5139. (Pubitemid 32397095)
41. Eakin CM, Maccoss MJ, Finney GL, Klevit RE. Estrogen receptor alpha is a putative substrate for the BRCA1 ubiquitin ligase. Proc Nat Acad Sci USA. 2007;104:5794-5799. (Pubitemid 47175613)
42. Pedram A, Razandi M, Levin ER. Nature offunctional estrogen receptors at the plasma membrane. Mol Endocrinol. 2006;20:1996-2009. (Pubitemid 44286700)
43. Razandi M, Pedram A, Rosen EM, Levin ER. BRCA1 inhibits membrane estrogen and growth factor receptor signaling to cell proliferation in breast cancer. Mol Cell Biol. 2004;24:5900-5913. (Pubitemid 38787974)
44. Zheng L, Annab LA, Afshari CA, Lee WH, Boyer TG. BRCA1 mediates ligand-inde-pendent transcriptional repression of the estrogen receptor. Proc Nat Acad Sci USA. 2001;98:9587-9592. (Pubitemid 32769347)
45. Jones LP, Li M, Halama ED, Ma Y, Lubet R, Grubbs CJ, Deng C-X, Rosen EM, Furth PA. Promotion of mammary cancer development by tamoxifen in a mouse model of Brca1-mutation related breast cancer. Oncogene 2005;24:3554-3562. (Pubitemid 40756225)
46. Ma Y, Hu C, Riegel AT, Fan S, Rosen EM. Growth factor signaling pathways modulate BRCA1 repression of estrogen receptor-alpha activity. Mol Endocrinol. 2007;21:1905-1923. (Pubitemid 47173800)
47. Mosselman S, Polman J, Dijkema R. ER-beta: identification and characterization of a novel human estrogen receptor. FEBS Lett. 1996;392:49-53. (Pubitemid 26268330)
48. Pettersson K, Delaunay F, Gustafsson JA. Estrogen receptor beta acts as a dominant regulator of estrogen signaling. Oncogene 2000;19:4970-4978.
49. Weihua Z, Saji S, Makinen S, Cheng G, Jensen EV, Warner M, Gustafsson JA. Estrogen receptor (ER) beta, a modulator of ER alpha in the uterus. Proc Nat Acad Sci USA. 2000;97:5936-5941. (Pubitemid 30367502)
50. Jisa E, Jungbauer A. Kinetic analysis of estrogen receptor homo-and heterodimerization in vitro. J Steroid Biochem Mol Biol. 2003;84:141-148. (Pubitemid 36514831)
51. Hall JM, McDonnell DP. The estrogen receptor betaisoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 1999;140:5566-5578. (Pubitemid 30645344)
52. Hu Y, Ghosh S, Amleh A, Yue W, Lu Y, Katz A, Li R. Modulation of aromatase expression by BRCA1: a possible link to tissue-specific tumor suppression. Oncogene 2005;24:8343-8348. (Pubitemid 43256356)
53. Lu M, Chen D, Lin Z, Reierstad S, Trauernicht AM, Boyer TG, Bulun SE. BRCA1 negatively regulates the cancer-associated aromatase promoters I.3 and II in breast adipose fibroblasts and malignant epithelial cells. J Clin Endocrinol Metab. 2006;91:4514-4519. (Pubitemid 44833433)
54. Subbaramaiah K, Hudis C, Chang SH, Hla T, Dannenberg AJ. EP2 and EP4 receptors regulate aromatase expression in human adipocytes and breast cancer cells. Evidence of a BRCA1 and p300 exchange. J Biol Chem. 2008;283:3433-3444.
55. Ma Y, Katiyar P, Jones LP, Fan S, Zhang Y, Furth PA, Rosen EM. The breast cancer susceptibility gene BRCA1 regulates progesterone receptor signaling in mammary epithe-lial cells. Mol Endocrinol. 2006;20:14-34. (Pubitemid 43011667)
56. Poole AJ, Li Y, Kim Y, Lin SC, Lee WH, Lee EY. Prevention of Brca1-mediatedmammary tumorigenesis in mice by a progesterone antagonist. Science 2006;314:1467-1470. (Pubitemid 44871955)
57. Henderson BE, Feigelson HS Hormonal carcinogenesis. Carcinogenesis 2000;21:427-433. (Pubitemid 30137927)
58. von Schoultz B. Androgens and the breast. Maturitas 2007;57:47-49 Review.
59. Park JJ, Irvine RA, Buchanan G, Koh SS, Park JM, Tilley WD, Stallcup MR, Press MF, Coetzee GA. Breast cancer susceptibility gene 1 (BRCA1) is a coactivator of the androgen receptor. Cancer Res. 2000;60:5946-5949.
60. Yeh S, Hu YC, Rahman M, Lin HK, Hsu CL, Ting HJ, Kang HY, Chang C Increase of androgen induced cell death and androgen receptor transactivation by BRCA1 in pros-tate cancer cells. Proc Nat Acad Sci USA. 2000;97:11256-11261.
61. Ando S, De Amicis F, Rago V, Carpino A, Maggiolini M, Panno ML, Lanzino M. Breast cancer: from estrogen to androgen receptor. Mol Cell Endocrinol. 2002;193:121-128. (Pubitemid 34823616)
62. Ferro P, Catalano MG, Dell'Eva R, Fortunati N, Pfeffer U. The androgen receptor CAG repeat: a modifier ofcarcinogenesis? Mol Cell Endocrinol. 2002;193:109-120. (Pubitemid 34823615)
63. Hakem R, de la Pompa JL, Mak TW. Developmental studies ofBrca1 and Brca2 knock-out mice. J Mammary Gland Biol Neoplasia. 1998;3: 431-445 Review.
64. Hakem R, de la Pompa JL, Elia A, Potter J, Mak TW. Partial rescue of Brca1 (5-6) early embryonic lethality by p53 or p21 null mutation. Nat Genet. 1997;16:298-302. (Pubitemid 27280216)
65. Lane TF, Deng C, Elson A, Lyu MS, Kozak CA, Leder P. Expression of Brca1 is associated with terminal differentiation ofectodermally and mesodermally derived tissues inmice. Genes Dev. 1995;9:2712-2722.
66. Marquis ST, Rajan JV, Wynshaw-Boris A, Xu J, Yin GY, Abel KJ, Weber BL, Chodosh LA. The developmentalpatternofBrca1 expressionimplies arole indifferentiationof the breast and other tissues. Nat Genet. 1995;11:17-26.
67. Kubista M, Rosner M, Kubista E, Bernaschek G, Hengstschlager M. Brca1 regulates in vitro differentiation ofmammary epithelial cells. Oncogene 2002;21:4747-4756. (Pubitemid 34879450)
68. Furuta S, Jiang X, Gu B, Cheng E, Chen PL, Lee WH. Depletion of BRCA1 impairs differentiation but enhances proliferation ofmammary epithelial cells. Proc Nat Acad Sci USA. 2005;102:9176-9181. (Pubitemid 40923537)
69. Rajan JV, Marquis ST, Gardner HP, Chodosh LD. Developmental expression of Brca2 colocalizes with Brca1 and is associated with proliferation and differentiation in multiple tissues. Devel Biol. 1997;184:385-40.
70. Bennett LM, McAllister KA, Malphurs J, Ward T, Collins NK, Seely JC, Gowen LC, Koller BH, Davis BJ, Wiseman RW. Mice heterozygous for a Brca1 or Brca2 mutation display distinct mammary gland and ovarian phenotypes in response to diethylstilbestrol. Cancer Res. 2000;60:3461-3469. (Pubitemid 30482165)
71. Xu X, Wagner K-U, Larson D, Weaver Z, Li C, Ried T, Hennighausen L, Wynshaw-Boris A, Deng C-X Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat Genet. 1999;22: 37-43. (Pubitemid 29214802)
72. Phillips KA, Andrulis IL, Goodwin PJ Breast carcinomas arising in carriers of muta-tions in BRCA1 or BRCA2 are they prognostically different? J Clin Oncol. 1999;17:3653-3663. (Pubitemid 29517937)
73. Lakhani SR, Van De Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L, Easton DF. The pathology of familial breast cancer predictive value of immunohisto-chemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients withmutations in BRCA1 and BRCA2. J Clin Oncol. 2002;20:2310-2318. (Pubitemid 34441658)
74. Brodie SG, Xu X, Qiao W, Li WM, Cao L, Deng CX Multiple genetic changes are associated with mammary tumorigenesis in Brca1 conditional knockout mice. Oncogene 2001;20:17514-17523.
75. Deng CX Tumor formation in Brca1 conditional mutant mice. Environ Mol Mutagen. 2002;39:171-177.
76. Jones LP, Tilli MT, Assefnia S, Torre K, Halama ED, Parrish A, Rosen EM, Furth PA. Activation of estrogen signaling pathways collaborates with loss of Brca1 to promote development of ERalpha-negative and ERalpha-positive mammary preneoplasia and cancer. Oncogene 2008;27:794-802. (Pubitemid 351186312)
77. Bachelier R, Xu X, Li C, Qiao W, Furth PA, Lubet RA, Deng CX. Effect of bilateral oophorectomy on mammary tumor formation in BRCA1 mutant mice. Oncol Rep. 2005;14:1117-1120.
78. Holmes MD, Willett WC Does diet affect breast cancer risk? Breast Cancer Res. 2004;6:170-178. (Pubitemid 39136486)
79. Linos E, Willett WC. Diet and breast cancer risk reduction. J Natl Compr Canc Netw. 2007;5:711-718 Review. (Pubitemid 47492769)
80. Fan S, Meng Q, Gao B, Grossman J, Yadegari M, Goldberg ID, Rosen EM. Alcohol stimulates estrogen receptor signaling in human breast cancer cell lines. Cancer Res. 2000;60:5635-5639.
81. Rattenborg T, Gjermandsen I, Bonefeld-Jorgensen EC Inhibition of E2-induced expres-sion of BRCA1 by persistent organochlorines. Breast Cancer Res. 2007;4:R12.
82. Jeffy BD, Chirnomas RB, Chen EJ, Gudas JM, Romagnolo DF. Activation of the aromatic hydrocarbon receptor pathway is not sufficient for transcriptional repression of BRCA-1: requirements for metabolism of benzo[a]pyrene to 7r,8t-dihydroxy-9t,10-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene. Cancer Res. 2002;62:113-121. (Pubitemid 34073994)
83. Hockings JK, Thorne PA, Kemp MQ, Morgan SS, Selmin O, Romagnolo DF. The ligand status of the aromatic hydrocarbon receptor modulates transcriptional activation of BRCA-1 promoter by estrogen. Cancer Res. 2006;66:2224-2232.
84. Kang HJ, Kim HJ, Kim SK, Barouki R, Cho CH, Khanna KK, Rosen EM, Bae I. BRCA1 modulates xenobiotic stress-inducible gene expression by interacting with ARNT in human breast cancer cells. J Biol Chem. 2006;281: 14654-14662. (Pubitemid 43855169)
85. Shertzer HG, Senft AP. The micronutrient indole-3-carbinol: implications for disease and chemoprevention. Drug Metab Drug Interact. 2000;17:159-188. (Pubitemid 32047534)
86. Bradlow HL, Michnovich J, Telang NT, Osborne MP. Effects ofdietary indole-3-carbi-nol on estradiol metabolism and spontaneous mammary tumors in mice. Carcinogenesis 1991;12:1571-1574.
87. Meng Q, Yuan F, Goldberg ID, Rosen EM, Auborn K, Fan S. Indole-3-carbinol is a negative regulator of estrogen receptor-alpha signaling in human tumor cells. J Nutr. 2000;130:2927-2931. (Pubitemid 32005319)
88. Meng Q, Qi M, Chen DZ, Yuan R, Goldberg ID, Rosen EM, Auborn K, Fan S. Suppression of breast cancer invasion and migration by indole-3-carbinol: associated with up-regulation of BRCA1 and E-cadherin/catenin complexes. J Mol Med. 2000;78:155-165. (Pubitemid 30337497)
89. Carter TH, Liu K, Ralph W Jr, Chen D, Qi M, Fan S, Yuan F, Rosen EM, Auborn KJ Diindolylmethane alters gene expression in human keratinocytes in vitro. J Nutr. 2002;132:3314-3324. (Pubitemid 35304238)
90. Fan S, Meng Q, Auborn K, Carter T, Rosen EM BRCA1 and BRCA2 as molecular targets for phytochemicals indole-3-carbinol and genistein in breast and prostate cancer cells. Br J Cancer. 2006;94:407-426. (Pubitemid 43237565)
91. Cabanes A, Wang M, Olivo S, DeAssis S, Gustafsson JA, Khan G, Hilakivi-Clarke L. Prepubertal estradiol and genistein exposures up-regulate BRCA1 mRNA and reduce mammary tumorigenesis. Carcinogenesis 2004;25:741-748. (Pubitemid 38618526)
92. Barkhem T, Carlsson B, Nilsson Y, Enmark E, Gustafsson J, Nilsson S. Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists. Mol Pharmacol. 1998;54:105-112. (Pubitemid 28337592)
93. Pike AC, Brzozowski AM, Hubbard RE, Bonn T, Thorsell AG, Engstrom O, Ljunggren J, Gustafsson JA, Carlquist M Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. EMBO J. 1999;18:4608-4618. (Pubitemid 29415516)
94. Yu B, Khan G, Foxworth A, Huang K, Hilakivi-Clarke L. Maternal dietary exposure to fiber during pregnancy and mammary tumorigenesis among rat offspring. Int J Cancer. 2006;119: 2279-2286. (Pubitemid 44546946)
95. Hilakivi-Clarke L, Olivo SE, Shajahan A, Khan G, Zhu Y, Zwart A, Cho E, Clarke R. Mechanisms mediating the effects ofprepubertal (n-3) polyunsaturated fatty acid diet on breast cancer risk in rats. J Nutr. 2005;135(12 Suppl):2946S-2952S Review. (Pubitemid 43156571)
96. Verhoog LC, Brekelmans CT, Seynaeve C, van den Bosch LM, Dahmen G, van Geel AN, Tilanus-Linthorst MM, Bartels CC, Wagner A, van den Ouweland A, Devilee P, Meijers-Heijboer EJ, Klijn JG. Survival and tumour characteristics of breast-cancer patients with germline mutations ofBRCA1. Lancet 1998;351:316-321. (Pubitemid 28052696)
97. Robson ME, Chappuis PO, Satagopan J, Wong N, Boyd J, Goffin JR, Hudis C Roberge D, Norton L, Begin LR, Offit K, Foulkes WD. A combined analysis of out-come following breast cancer differences in survival based on BRCA1/BRCA2 mutation status and administration ofadjuvant treatment. Breast Cancer Res. 2004;6:R8-R17.
98. Reis-Filho JS, Tutt AN Triple negative tumours: a critical review. Histopathology 2008;52:108-118 Review.
99. Archey WB, McEachern KA, Robson M, Offit K, Vaziri SA, Casey G, Borg A, Arrick BA. Increased CpG methylation of the estrogen receptor gene in BRCA1-linked estro-gen receptor-negative breast cancers. Oncogene 2002;21:7034-7041. (Pubitemid 35252977)
100. Hosey AM, Gorski JJ, Murray MM, Quinn JE, Chung WY, Stewart GE, James CR, Farragher SM, Mulligan JM, Scott AN, Dervan PA, Johnston PG, Couch FJ, Daly PA, Kay E, McCann A, Mullan PB, Harkin DP. Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer. J Natl Cancer Inst. 2007;99:1683-1694. (Pubitemid 351767217)
101. Ozcelik H, To MD, Couture J, Bull SB, Andrulis IL. Preferential allelic expression can lead to reduced expression of BRCA1 in sporadic breast cancers. Int J Cancer. 1998;77:1-6. (Pubitemid 28308543)
102. Taylor J, Lymboura M, Pace PE, A'hern RP, Desai AJ, Shousha S, Coombes RC, Ali S. An important role for BRCA1 in breast cancer progression is indicated by its loss in a large proportion ofnonfamilial breast cancers. Int J Cancer. 1998;79:334-342. (Pubitemid 28359729)
103. Rio PG, Maurizis JC, Peffault de Latour M, Bignon YJ, Bernard-Gallon DJ. Quanti-fication of BRCA1 protein in sporadic breast carcinoma with or without loss of hetero-zygosity of the BRCA1 gene. Int J Cancer. 1999;80:823-826. (Pubitemid 29108855)
104. Wilson CA, Ramos L, Villasenor MR, Anders KH, Press MF, Clarke K, Karlan B, Chen JJ, Scully R, Livingston D, Zuch RH, Kanter MH, Cohen S, Calzone FJ, Slamon DJ. Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas. Nat Genet. 1999;21:236-240. (Pubitemid 29070375)
105. Rice JC, Massey-Brown KS, Futscher BW. Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells. Oncogene 1998;17:1807-1812. (Pubitemid 28482783)
106. Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E, Bussaglia E, Prat J, Harkes IC, Repasky EA, Gabrielson E, Schutte M, Baylin SB, Herman JG. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst. 2000;92:564-569. (Pubitemid 30212318)
107. Staff S, Isola J, Tanner M Haplo-insufficiency of BRCA1 in sporadic breast cancer. Cancer Res. 2003;63:4978-4983. (Pubitemid 37022634)
108. Butcher DT, Rodenhiser DI. Epigenetic inactivation of BRCA1 is associated with aberrant expression of CTCF and DNA methyltransferase (DNMT3B) in some spora-dic breast tumours. Eur J Cancer. 2007;43:210-219. (Pubitemid 46070215)
109. MacDonald G, Stramwasser M, Mueller CR. Characterization of a negative transcrip-tional element in the BRCA1 promoter. Breast Cancer Res. 2007;9:R49.
110. Wang C, Fan S, Li Z, Fu M, Rao M, Ma Y, Lisanti MP, Albanese C, Katzenellenbogen BS, Kushner PJ, Weber B, Rosen EM, Pestell RG. Cyclin D1 antagonizes BRCA1 repression of estrogen receptor alpha activity. Cancer Res. 2005;65:6557-6567. (Pubitemid 41060691)